{"disease":{"id":"huntington-disease","name":"huntington disease"},"drugs":{"marketed":[{"drug_id":"valbenazine","indication_name":"Chorea Associated with Huntington’s Disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ingrezza","generic_name":"valbenazine","company_name":"Neurocrine","drug_phase":"marketed","molecular_target":"Potassium voltage-gated channel subfamily H member 2, Synaptic vesicular amine transporter, Synaptic vesicular amine transporter","drug_class":"","quality_score":55,"revenue":"1900","mechanism":null},{"drug_id":"deutetrabenazine","indication_name":"Chorea associated with Huntington’s disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Austedo","generic_name":"DEUTETRABENAZINE","company_name":"Teva","drug_phase":"marketed","molecular_target":"Synaptic vesicular amine transporter","drug_class":"","quality_score":70,"revenue":"1100","mechanism":"Austedo works by binding to the synaptic vesicular amine transporter, reducing the release of dopamine and other neurotransmitters."}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06209515","title":"Sociodemographic Factors and Criminal Behaviour Preceding Neurodegenerative Disease - Retrospective Register Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":61292,"lead_sponsor_name":"Kuopio University Hospital","has_results":false},{"nct_id":"NCT06203106","title":"NYSCF Scientific Discovery Biobank","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"New York Stem Cell Foundation Research Institute","has_results":false},{"nct_id":"NCT02855476","title":"HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease","phase":"","overall_status":"RECRUITING","enrollment_count":2500,"lead_sponsor_name":"University College, London","has_results":false},{"nct_id":"NCT03233646","title":"Retinal Imaging in Neurodegenerative Disease","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Duke University","has_results":false},{"nct_id":"NCT04270604","title":"Biological Sample Collection for Research and Biobanking","phase":"","overall_status":"TERMINATED","enrollment_count":1279,"lead_sponsor_name":"New York Stem Cell Foundation Research Institute","has_results":false},{"nct_id":"NCT00052143","title":"Prospective Huntington At Risk Observational Study","phase":"","overall_status":"COMPLETED","enrollment_count":1001,"lead_sponsor_name":"Huntington Study Group","has_results":false},{"nct_id":"NCT06539169","title":"FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"xCures","has_results":false},{"nct_id":"NCT03761849","title":"A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Participants With Manifest Huntington's Disease","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":899,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT07326709","title":"A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":770,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05268029","title":"Making HD Voices Heard","phase":"","overall_status":"COMPLETED","enrollment_count":698,"lead_sponsor_name":"Huntington Study Group","has_results":false},{"nct_id":"NCT06667414","title":"Frequency of Selected Single Nucleotide Polymorphisms in Huntington Disease Gene Expansion Carriers","phase":"","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT04556656","title":"PRidopidine's Outcome On Function in Huntington Disease, PROOF- HD","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":499,"lead_sponsor_name":"Prilenia","has_results":true},{"nct_id":"NCT00665223","title":"A Study of Treatment With Pridopidine (ACR16) in Participants With Huntington's Disease","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":437,"lead_sponsor_name":"Teva Branded Pharmaceutical Products R&D, Inc.","has_results":true},{"nct_id":"NCT02006472","title":"A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Vs Placebo for Symptomatic Treatment in Patients With Huntington's Disease","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":408,"lead_sponsor_name":"Prilenia","has_results":true},{"nct_id":"NCT02215616","title":"A Clinical Study in Participants With Huntington's Disease (HD) to Assess Efficacy and Safety of Three Oral Doses of Laquinimod","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":352,"lead_sponsor_name":"Teva Branded Pharmaceutical Products R&D, Inc.","has_results":true},{"nct_id":"NCT00491842","title":"Individuals Patterns of Disclosure About Huntington s Disease (HD) and the Association With Adaptation to HD","phase":"","overall_status":"COMPLETED","enrollment_count":315,"lead_sponsor_name":"National Human Genome Research Institute (NHGRI)","has_results":false},{"nct_id":"NCT05686551","title":"GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":301,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT04818060","title":"Preparing for Prevention of Huntington's Disease (PREVENT-HD)","phase":"","overall_status":"COMPLETED","enrollment_count":258,"lead_sponsor_name":"University of Wisconsin, Madison","has_results":false},{"nct_id":"NCT02494778","title":"A Study Evaluating if Pridopidine is Safe, Efficacious, and Tolerable in Patients With Huntington's Disease","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":248,"lead_sponsor_name":"Prilenia","has_results":true},{"nct_id":"NCT03842969","title":"An Open-Label Extension Study to Evaluate Long-Term Safety and Tolerability of RO7234292 (RG6042) in Huntington's Disease Participants Who Participated in Prior Roche and Genentech Sponsored Studies","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":236,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT03628235","title":"HD-Charge: Indirect and Out-of-Pocket Costs of Huntington's Disease in the United States","phase":"","overall_status":"COMPLETED","enrollment_count":233,"lead_sponsor_name":"CHDI Foundation, Inc.","has_results":false},{"nct_id":"NCT00724048","title":"A Study of Pridopidine (ACR16) for the Treatment of Participants With Huntington's Disease","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":227,"lead_sponsor_name":"Teva Branded Pharmaceutical Products R&D, Inc.","has_results":true},{"nct_id":"NCT04231487","title":"Using Wearable and Mobile Data to Diagnose and Monitor Movement Disorders","phase":"","overall_status":"UNKNOWN","enrollment_count":210,"lead_sponsor_name":"Rutgers, The State University of New Jersey","has_results":false},{"nct_id":"NCT05107128","title":"A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease (HD)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":189,"lead_sponsor_name":"Supernus Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT02342548","title":"Open Label Extension Study To Investigate Long Term Safety, Tolerability And Efficacy Of Pf-02545920 In Subjects With Huntington's Disease Who Completed Study A8241021","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":188,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT05509153","title":"A Randomised Controlled Trial, Of N-Acetyl Cysteine (NAC), for Premanifest Huntingtin Gene Expansion Carriers","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":160,"lead_sponsor_name":"Western Sydney Local Health District","has_results":false},{"nct_id":"NCT05358717","title":"A Study to Evaluate the Safety and Efficacy of PTC518 in Participants With Huntington's Disease (HD)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":159,"lead_sponsor_name":"PTC Therapeutics","has_results":true},{"nct_id":"NCT06391619","title":"Huntington's Disease Young Adult Study 2.0","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":154,"lead_sponsor_name":"University College, London","has_results":false},{"nct_id":"NCT05655520","title":"A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's Disease","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":153,"lead_sponsor_name":"Supernus Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT04630574","title":"Characterization and Quantification of Motor Speech Disorders in Huntington's Disease: Identification of Acoustic Markers","phase":"","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"University Hospital, Bordeaux","has_results":false},{"nct_id":"NCT06254482","title":"An Extension Study to Evaluate the Long-Term Safety and Efficacy of Votoplam in Participants With Huntington's Disease (HD)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":144,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT01306929","title":"Open-label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington Disease","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":134,"lead_sponsor_name":"Prilenia","has_results":true},{"nct_id":"NCT06343220","title":"Project AWARE 2.0 to Improve Awareness, Willingness and Ability for Research and Enrollment in Clinical Research","phase":"","overall_status":"COMPLETED","enrollment_count":131,"lead_sponsor_name":"Huntington Study Group","has_results":false},{"nct_id":"NCT06097780","title":"Efficacy and Safety of NestaCell® in Huntington's Disease","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":120,"lead_sponsor_name":"Azidus Brasil","has_results":false},{"nct_id":"NCT02994719","title":"Gait Analysis in Neurological Disease","phase":"","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"Beth Israel Deaconess Medical Center","has_results":false},{"nct_id":"NCT01897896","title":"Alternatives for Reducing Chorea in Huntington Disease","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":119,"lead_sponsor_name":"Auspex Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT03344601","title":"PHysical Activity and Exercise Outcomes in Huntington's Disease","phase":"NA","overall_status":"UNKNOWN","enrollment_count":116,"lead_sponsor_name":"Cardiff University","has_results":false},{"nct_id":"NCT03434548","title":"IMarkHD: in Vivo Longitudinal Imaging of HD Pathology","phase":"","overall_status":"RECRUITING","enrollment_count":113,"lead_sponsor_name":"King's College London","has_results":false},{"nct_id":"NCT02507284","title":"Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":106,"lead_sponsor_name":"Azevan Pharmaceuticals","has_results":true},{"nct_id":"NCT05238701","title":"A Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of LPM3770164 in Healthy Subjects","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":104,"lead_sponsor_name":"Luye Pharma Group Ltd.","has_results":false},{"nct_id":"NCT05943054","title":"Striatum and Hippocampus on Different Time Scales","phase":"NA","overall_status":"UNKNOWN","enrollment_count":104,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT03417583","title":"Assessing Efficacy of Neuropsychiatric Assessment and Treatment Protocols in Huntington's Disease Patients","phase":"NA","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Vanderbilt University Medical Center","has_results":false},{"nct_id":"NCT02453061","title":"A Comparative Phase 2 Study Assessing the Efficacy of Triheptanoin, an Anaplerotic Therapy in Huntington's Disease","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Institut National de la Santé Et de la Recherche Médicale, France","has_results":false},{"nct_id":"NCT07010705","title":"Digital Measures for Clinical Trial Endpoints in Huntington's Disease","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"University of Rochester","has_results":false},{"nct_id":"NCT03664804","title":"Study to Measure Cerebrospinal Fluid Mutant Huntingtin Protein in Participants With Early Manifest Stage I or Stage II Huntington's Disease","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":95,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT05534139","title":"Clinicopathological MRI and CSF Correlates in Huntington's Disease.","phase":"","overall_status":"UNKNOWN","enrollment_count":90,"lead_sponsor_name":"Leiden University Medical Center","has_results":false},{"nct_id":"NCT04925622","title":"Complex Eye Movements in Parkinson's Disease and Related Movement Disorders","phase":"","overall_status":"COMPLETED","enrollment_count":90,"lead_sponsor_name":"Saccadous, Inc.","has_results":false},{"nct_id":"NCT03225846","title":"Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":88,"lead_sponsor_name":"Wave Life Sciences Ltd.","has_results":true},{"nct_id":"NCT03421327","title":"Genetic Risk: Whether, When, and How to Tell Adolescents","phase":"","overall_status":"COMPLETED","enrollment_count":85,"lead_sponsor_name":"Johns Hopkins University","has_results":false},{"nct_id":"NCT02639871","title":"Dynamic Neuroimaging Biomarkers in Huntington's Disease","phase":"","overall_status":"COMPLETED","enrollment_count":81,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}